.png)
TL;DRPIL stands for package leaflet, sometimes called the patient information leaflet or package insert. It is the document supplied inside the pack of a medicine and written for the person taking it, known in Germany as the Packungsbeilage or Gebrauchsinformation.
The package leaflet is not an independent text. It is derived from the Summary of Product Characteristics (SmPC), the professional information a competent authority approves with the marketing authorisation. The direction is fixed in law: the leaflet simplifies the approved reference document for a lay reader, and it may omit detail, but it may never contradict it. For the professional document itself, its ten sections and the way updates flow through it, see the SmPC entry.
Two layers apply in Germany at once. At EU level, Article 59 of Directive 2001/83/EC opens with the rule that the package leaflet "shall be drawn up in accordance with the summary of the product characteristics", then fixes the content and its order. At national level, § 11 of the Arzneimittelgesetz (AMG) requires the leaflet to carry that information in agreement with the Fachinformation ("in Übereinstimmung mit den Angaben nach § 11a") and to be written in generally comprehensible German and in legible type ("allgemein verständlich in deutscher Sprache, in gut lesbarer Schrift").
There is a second requirement that sets the leaflet apart from every other regulatory document: it has to be tested on real readers. Article 59(3) states that the package leaflet "shall reflect the results of consultations with target patient groups to ensure that it is legible, clear and easy to use". In practice a leaflet reaches and stays with a patient like this:
Article 59(1) sets the sequence. The headings a patient sees are usually phrased as everyday questions, but they map onto the legal list below.
| Order (Article 59) | What it covers |
|---|---|
| (a) Identification | Name, strength and pharmaceutical form, and the pharmaco-therapeutic group in terms the patient can understand |
| (b) Therapeutic indications | What the medicine is used for |
| (c) Before taking | Contraindications, precautions for use, interactions, special warnings |
| (d) Instructions for use | Dosage, method and route, frequency, duration, overdose and missed-dose guidance |
| (e) Adverse reactions | Side effects that may occur, what to do, and how to report them |
| (f) Expiry and storage | Expiry date, storage precautions, full composition, marketing authorisation holder and manufacturer |
| (h) Revision date | The date the leaflet was last revised, which is the version stamp |
Point (g), a list of the names under which the medicine is authorised in other Member States, appears only where that applies, which is why an ordinary leaflet is usually described in terms of the blocks above plus the revision date.
They are not two reading levels of one text, they are two documents with a fixed relationship. The SmPC is the approved reference written for healthcare professionals, and the package leaflet is derived from it for the patient. The audience differs, the language level differs, and where the two appear to disagree the SmPC governs, because Article 59 binds the leaflet to it. The full side-by-side comparison, audience, legal status, who approves each, and language level, sits in the SmPC entry and is not repeated here.
pharmazie.com attaches the documents to the article record itself, so a professional arrives at the leaflet from the PZN rather than searching by product name. The Packungsbeilage sits alongside the Fachinformation as an ABDA PlusX document, each carrying its own Stand date, and ChatPIL®, a chat trained on the package leaflets, is embedded at the same article.
One honest limitation: a database copy of a leaflet is a copy, and its Stand date is the point of the field, not decoration. The Packungsbeilage and the Fachinformation for the same pack routinely carry different dates, because they are revised through separate steps. Where a decision turns on the exact approved wording, the authoritative version is the one supplied by the marketing authorisation holder, not any aggregated copy.
